Consensus ACADIA Pharmaceuticals Inc.

Stocks

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-10 EDT			5-day change	1st Jan Change
27.74 ^USD	+0.22%		-0.43%	+3.86%

08-25	Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating	MT
08-25	EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu	MT

Evolution of the Average Target: ACADIA Pharmaceuticals Inc.

Evolution of the Target Price: ACADIA Pharmaceuticals Inc.

Changes in Analyst Recommendations: ACADIA Pharmaceuticals Inc.

6ed1871e9.yKFSHfz7WlY7Sifa4inrEaoE5SGFwcVHpsKVuKAk4Ic.-vELSbGUDBcMEwqAlHbZR89yo1TzqZQNko7h8sNJpO6q9RBX0Zg3Ag9_Fw~3d4fc695f1e911df7adba7231215541d

Analysts' recommendations: ACADIA Pharmaceuticals Inc.

08-25	Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating	MT
08-17	UBS Adjusts Price Target on ACADIA Pharmaceuticals to $49 From $45, Maintains Buy Rating	MT
08-10	Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating	MT
08-05	ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says	MT
08-05	Oppenheimer Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $23, Maintains Perform Rating	MT
08-05	RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating	MT
07-07	RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating	MT
06-29	Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating	MT
04-07	RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating	MT
03-25	ACADIA Pharmaceuticals Shares Rise After BofA Upgrade	MT
03-25	BofA Securities Upgrades ACADIA Pharmaceuticals to Buy From Neutral, Price Target is $29	MT
03-24	Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says	MT
02-26	RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $31, Keeps Outperform Rating	MT
02-26	Morgan Stanley Lifts Price Target on ACADIA Pharmaceuticals to $26 From $25, Keeps Equalweight Rating	MT
02-23	Acadia Pharmaceuticals Shares Rise After Mizuho Upgrade	MT
02-23	Mizuho Upgrades ACADIA Pharmaceuticals to Outperform From Neutral, Adjusts Price Target to $35 From $29	MT
02-03	Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says	MT
02-03	RBC Cuts Price Target on ACADIA Pharmaceuticals to $31 From $35, Keeps Outperform Rating	MT
02-03	Deutsche Bank Trims Price Target on ACADIA Pharmaceuticals to $32 From $33, Keeps Buy Rating	MT
01-20	RBC Raises Price Target on ACADIA Pharmaceuticals to $35 From $33, Keeps Outperform Rating	MT
01-08	RBC Lifts Price Target on ACADIA Pharmaceuticals to $33 From $32, Keeps Outperform Rating	MT
01-06	UBS Adjusts Price Target on ACADIA Pharmaceuticals to $40 From $35, Maintains Buy Rating	MT
12-04	UBS Adjusts ACADIA Pharmaceuticals Price Target to $35 From $39, Maintains Buy Rating	MT
11-06	RBC Cuts Price Target on ACADIA Pharmaceuticals to $32 From $34, Keeps Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ACADIA PHARMACEUTICALS INC.					+22.83%
	LONZA GROUP AG					+27.91%
	REVOLUTION MEDICINES, INC.					+20.96%
	IQVIA HOLDINGS INC.					+7.51%
	BEONE MEDICINES AG					+23.2%
	CELLTRION, INC.					+46.49%
	ASCENDIS PHARMA A/S					+20.62%
	MEDPACE HOLDINGS, INC.					-0.76%
	EUROFINS SCIENTIFIC SE					+1.84%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+0.95%
	Average					+17.16%
	Weighted average by Cap.					+20.18%